The Mobius 2000-L single-use bioreactor from EMD Millipore offers configurable software, hardware, and single-use Flexware assemblies for suspension and adherent cell-culture applications.
The Mobius 2000-L single-use bioreactor from EMD Millipore, the Life Science business of Merck KGaA, joins the Mobius stirred tank bioreactor portfolio that now ranges from 3 to 2000 L. Features include configurable software, hardware, and single-use Flexware assemblies for suspension and adherent cell-culture applications.
The bioreactor features the industry's first pull-out drawer and self-deploying bag, which makes Flexware assembly installation and inflation safe and easy. This design minimizes operator intervention and requires no hoist during Flexware assembly installation and removal. A patent-pending baffle design creates homogenous mixing. The 5:1 turndown ratio allows users to inoculate and harvest at lower volumes, creating a wider, more flexible process window for seeding, growth, and collection strategies.
The bioreactor includes an external SensorReady loop connected to the Flexware assembly to provide greater flexibility for process monitoring and control. Unlike traditional bioreactors in which sensors are inserted into the Flexware assembly, the SensorReady loop enables users to incorporate additional sensors without modifying the Flexware assembly.
The Mobius bioreactor can be supplied as a fully integrated system with intuitive GMP-compliant software that reduces the learning curve for operators and allows for easy integration into plant automation strategies. The automation is simple and enables users to easily customize and control their processes. For customers with plant-wide common automation strategies, the single-use bioreactor can be integrated into third-party automation platforms.
Source: EMD Millipore
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.